What happened
The Cambridge, Massachusetts-based company originally received a $ 483 billion award, in support of its vaccine candidate mRNA-1273, as part of its contract with the Advanced Biomedical Research and Development Authority (BARDA). Now that amount is increasing to $ 955 million, as Moderna hopes to conduct Phase 3 trials with significantly more participants.
The biotech firm revealed that its phase 3 study, to be carried out in collaboration with the National Institute of Allergy and Infectious Diseases led by Anthony Fauci, will begin on Monday. The test would include 30,000 participants in the United States.
Because it is important
“We are very close to the vaccine, I think we are going to have very good results,” Trump said Tuesday.
Price action
Moderna’s shares closed 2.8% lower at $ 73.21 on Friday and were trading around 1.1% higher in the after-hours session.
Related
